Please wait

 

Alkermes Contacts:

 

 

For Investors:

Sandy Coombs +1 781 609 6377

 

For Media:

Katie Joyce +1 781 249 8927

 

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

— Total Revenues of $1.48 Billion in 2025; Net Sales of Proprietary Products Increased Approximately 9% Year-Over-Year —

— GAAP Net Income of $242 Million and Diluted GAAP Earnings per Share of $1.43 for 2025 —

— Alixorexton Phase 3 Clinical Program in Narcolepsy Expected to Initiate in Q1 2026 —

— Recent Completion of Avadel Acquisition Strengthens Leadership Position in Sleep Medicine —

 

DUBLIN, Feb. 25, 2026 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026.

 

“Enabled by our strong operational and financial performance in 2025, Alkermes enters 2026 in a position of great strength, both financially and in terms of the opportunity to create value for shareholders through the development of important new medicines with significant market potential,” said Richard Pops, Chief Executive Officer of Alkermes. “As we look ahead, our strategic priorities for the year are clear: drive strong performance across our portfolio of commercial products, including LUMRYZ® (sodium oxybate) following the recently completed acquisition of Avadel; for alixorexton, initiate phase 3 studies designed to support a best-in-class profile in narcolepsy and complete our phase 2 study in idiopathic hypersomnia; and advance additional orexin candidates into phase 2 development in attention-deficit hyperactivity disorder and fatigue associated with multiple sclerosis and Parkinson’s disease. With strong momentum and a clear strategic vision, we are well positioned to deliver meaningful innovation and drive value in the years ahead.”

 

“In 2025, we generated total revenue of approximately $1.48 billion, strong profitability and cash flow. These results highlight the strength of our commercial portfolio and our continued focus on disciplined expense management,” said Joshua Reed, Chief Financial Officer of Alkermes. “As reflected in our financial expectations, in 2026 we are poised to drive robust cash generation and profitability while rapidly advancing alixorexton in registrational studies and progressing the clinical program for additional orexin 2 receptor agonists in our portfolio. The completed acquisition of Avadel enhances our financial profile, broadens our commercial capabilities, and accelerates our entry into the sleep medicine market. This positions us well for the potential future launch of alixorexton. With a solid balance sheet, a diversified revenue base, and a focused capital allocation strategy, we believe Alkermes is well‑positioned to deliver long-term growth and shareholder value.”

 

Key Financial Highlights

Revenues

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

(In millions)

2025

2024

 

2025

2024

Total Revenues

$

384.5

$

430.0

 

$

1,475.9

$

1,557.6

Total Proprietary Net Sales

$

315.5

$

307.7

 

$

1,184.6

$

1,083.5

     VIVITROL®

$

124.1

$

134.1

 

$

467.9

$

457.3

     ARISTADA®i

$

97.2

$

96.6

 

$

370.0

$

346.2

     LYBALVI®

$

94.1

$

77.0

 

$

346.7

$

280.0

 

1

 

Profitability

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

(In millions)

2025

2024

 

2025

2024

GAAP Net Income From Continuing Operations

$

49.3

$

145.7

 

$

241.7

$

372.1

GAAP Net Income (Loss) From Discontinued Operations

$

—

$

0.8

 

$

—

$

(5.1)

GAAP Net Income

$

49.3

$

146.5

 

$

241.7

$

367.1

 

 

 

 

 

 

 

 

 

 

EBITDA From Continuing Operations

$

64.4

$

170.0

 

$

285.6

$

452.4

EBITDA From Discontinued Operations

$

—

$

1.1

 

$

—

$

(5.8)

EBITDA

$

64.4

$

171.1

 

$

285.6

$

446.6

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

100.3

$

191.9

 

$

394.0

$

543.3

 

Revenue Highlights

Proprietary Product Revenues

•
LYBALVI revenues for the fourth quarter were $94.1 million. Fourth quarter revenues and total prescriptions grew 22% and 25%, respectively, compared to the fourth quarter of 2024.
•
ARISTADAi revenues for the fourth quarter were $97.2 million.
•
VIVITROL revenues for the fourth quarter were $124.1 million.

Manufacturing & Royalty Revenues

•
VUMERITY® manufacturing and royalty revenues for the fourth quarter were $27.6 million.
•
Royalty revenues from XEPLION®, INVEGA TRINZA®/TREVICTA® and INVEGA HAFYERA®/BYANNLI® for the fourth quarter were $31.3 million.

 

Key Operating Expenses

Please see Note 1 below for details regarding discontinued operations.

 

 

Three Months Ended

December 31,

 

Twelve Months Ended

December 31,

(In millions)

2025

2024

 

2025

2024

R&D Expense – Continuing Operations

$

93.0

$

58.2

 

$

324.0

$

245.3

R&D Expense – Discontinued Operations

$

—

$

(1.1)

 

$

—

$

5.8

 

 

 

 

 

 

 

 

 

 

SG&A Expense – Continuing Operations

$

187.2

$

147.0

 

$

701.5

$

645.2

SG&A Expense – Discontinued Operations

$

—

$

—

 

$

—

$

—

 

Balance Sheet

•
At Dec. 31, 2025, the company recorded cash, cash equivalents, restricted cash and total investments of $1.32 billion, compared to $824.8 million at Dec. 31, 2024.
•
To finance the acquisition of Avadel Pharmaceuticals plc (Avadel), which closed in February 2026, the company used approximately $775 million of cash from its balance sheet and entered into term loans totaling $1.525 billion due in 2031.

2

 

Financial Expectations for 2026

All line items are according to GAAP, except as otherwise noted.

 

(In millions)

2026 Expectations

Total Revenues

$1,730 – $1,840

VIVITROL Net Sales

$460 – $480

LYBALVI Net Sales

$380 – $400

ARISTADAi Net Sales

$365 – $385

LUMRYZ Net Sales a

 

$315 – $335

Cost of Goods Sold b

$365 – $385

R&D Expenses

$445 – $485

SG&A Expenses

$890 – $930

Amortization of Intangible Assets c

 

$95 – $105

Net Interest Expense

$75 – $85

Net Tax Benefit

 

~$20

GAAP Net Loss d

 

($115) – ($135)

EBITDA

$60 – $90

Adjusted EBITDA

 $370 – $410

 

a

The acquisition of Avadel closed on Feb. 12, 2026. Expected net sales of LUMRYZ represents the period of Feb. 12, 2026 – Dec. 31, 2026. Avadel recorded net sales of LUMRYZ of approximately $33 million between Jan. 1, 2026 and Feb. 11, 2026.

b

In connection with the acquisition of Avadel, the company expects to record approximately $180 million of LUMRYZ inventory fair value step-up; approximately $150 million of this amount will be expensed as inventory is sold in 2026.

c

In connection with the acquisition of Avadel, the company expects to record approximately $1.5 billion of intellectual property related to LUMRYZ, which will be amortized over an expected life of 13 years.

d

Expected 2026 weighted average basic share count of approximately 169.1 million shares outstanding and a weighted average diluted share count of approximately 172.8 million shares outstanding.

 

Notes and Explanations

1.
The company determined that upon the separation of its former oncology business, completed on Nov. 15, 2023, the oncology business met the criteria for discontinued operations in accordance with Financial Accounting Standards Board Accounting Standards Codification 205, Discontinued Operations. Accordingly, the accompanying selected financial information has been updated to present the results of the oncology business as discontinued operations for the three and twelve months ended Dec. 31, 2024.

 

Conference Call

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. EST (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes’ website.

 

About Alkermes plc

Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

 

3

 

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including EBITDA and Adjusted EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

 

EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share-based compensation expense and non-recurring gains or losses in addition to the components of EBITDA from earnings.

 

The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non-GAAP financial measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA and Adjusted EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA and Adjusted EBITDA should not be considered measures of the company’s liquidity.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

 

Note Regarding Forward-Looking Statements

Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company’s expectations concerning its future financial and operating performance, business plans or prospects, including expected drivers of growth, value creation and profitability and the anticipated outcomes and benefits of the completed acquisition; and the company’s expectations regarding development plans, activities and timelines for, and the potential therapeutic and commercial value of, alixorexton and the company’s other development candidates. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the company is able to achieve its financial expectations, including those related to value creation and profitability; the businesses of Alkermes and Avadel may not be effectively integrated and the expected benefits and value of the acquisition may not be achieved; there may be unknown or inestimable liabilities and potential litigation associated with the acquisition; clinical development activities may not be completed on time or at all; the results of the company’s development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; the unfavorable outcome of arbitration, litigation, or other proceedings or disputes related to the company’s products or products using the company’s proprietary technologies; the company’s products or product candidates could be shown to be ineffective or unsafe; the U.S. Food and Drug Administration (FDA) or regulatory authorities outside the U.S. may not agree with the company’s regulatory approval strategies or may make adverse decisions regarding the company’s products; the company may not be able to achieve the expected benefits of the acquisition of Avadel and may not successfully integrate Avadel’s business; the company and its licensees may not be able to continue to successfully commercialize their products or support revenue growth from such products; potential changes in the cost, scope and duration of the company’s development programs; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to government payers; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on

4

 

the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

 

VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited, used by Alkermes, Inc. under license; LUMRYZ® is a registered trademark of Flamel Ireland Limited, an affiliate of Alkermes plc; BYANNLI®, INVEGA HAFYERA®, INVEGA TRINZA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.

 

 

(tables follow)

 

i

 The term “ARISTADA” as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.

 

5

 

Alkermes plc and Subsidiaries

 

Selected Financial Information (Unaudited)

 

 

 

 

 

 

 

 

Condensed Consolidated Statements of Operations - GAAP

 

Three Months Ended

 

 

Three Months Ended

 

(In thousands, except per share data)

 

December 31, 2025

 

 

December 31, 2024

 

Revenues:

 

 

 

 

Product sales, net

 

$

315,492

 

 

$

307,726

 

Manufacturing and royalty revenues

 

 

69,055

 

 

 

122,260

 

Total Revenues

 

 

384,547

 

 

 

429,986

 

Expenses:

 

 

 

 

Cost of goods manufactured and sold

 

 

46,209

 

 

 

62,116

 

Research and development

 

 

93,038

 

 

 

58,174

 

Selling, general and administrative

 

 

187,196

 

 

 

146,994

 

Amortization of acquired intangible assets

 

 

—

 

 

 

14

 

Total Expenses

 

 

326,443

 

 

 

267,298

 

Operating Income

 

 

58,104

 

 

 

162,688

 

Other Income, net:

 

 

 

 

 

 

Interest income

 

 

12,130

 

 

 

11,400

 

Interest expense

 

 

(12,277

)

 

 

(4,648

)

Other income, net

 

 

2,420

 

 

 

449

 

Total Other Income, net

 

 

2,273

 

 

 

7,201

 

Income Before Income Taxes

 

 

60,377

 

 

 

169,889

 

Income Tax Provision

 

 

11,036

 

 

 

24,152

 

Net Income From Continuing Operations

 

 

49,341

 

 

 

145,737

 

Income From Discontinued Operations — Net of Tax

 

 

—

 

 

 

766

 

Net Income — GAAP

 

$

49,341

 

 

$

146,503

 

 

 

 

 

 

 

GAAP Earnings Per Ordinary Share - Basic:

 

 

 

 

 

 

From continuing operations

 

$

0.30

 

 

$

0.90

 

From discontinued operations

 

$

—

 

 

$

0.00

 

From net income

 

$

0.30

 

 

$

0.90

 

 

 

 

 

 

 

GAAP Earnings Per Ordinary Share - Diluted:

 

 

 

 

 

 

From continuing operations

 

$

0.29

 

 

$

0.88

 

From discontinued operations

 

$

—

 

 

$

0.00

 

From net income

 

$

0.29

 

 

$

0.88

 

 

 

 

 

 

 

Weighted Average Number of Ordinary Shares Outstanding:

 

 

 

 

 

 

Basic — GAAP and Non-GAAP

 

 

165,334

 

 

 

161,956

 

Diluted — GAAP and Non-GAAP

 

 

169,539

 

 

 

166,554

 

 

 

 

 

 

 

An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows:

 

Net Income from Continuing Operations

 

$

49,341

 

 

$

145,737

 

Adjustments:

 

 

 

 

 

 

Depreciation expense

 

 

3,828

 

 

 

6,833

 

Amortization expense

 

 

19

 

 

 

14

 

Interest income

 

 

(12,130

)

 

 

(11,400

)

Interest expense

 

 

12,277

 

 

 

4,648

 

Income tax provision

 

 

11,036

 

 

 

24,152

 

EBITDA from Continuing Operations

 

 

64,371

 

 

 

169,984

 

EBITDA from Discontinued Operations

 

 

—

 

 

 

1,120

 

EBITDA

 

$

64,371

 

 

$

171,104

 

Share-based compensation

 

 

26,275

 

 

 

20,747

 

Costs related to the acquisition of Avadel

 

 

9,662

 

 

 

—

 

Adjusted EBITDA

 

$

100,308

 

 

$

191,851

 

 

6

 

Alkermes plc and Subsidiaries

 

Selected Financial Information (Unaudited)

 

 

 

 

 

 

 

 

Condensed Consolidated Statements of Operations - GAAP

 

Year Ended

 

 

Year Ended

 

(In thousands, except per share data)

 

December 31, 2025

 

 

December 31, 2024

 

Revenues:

 

 

 

 

Product sales, net

 

$

1,184,643

 

 

$

1,083,534

 

Manufacturing and royalty revenues

 

 

291,256

 

 

 

474,095

 

Research and development revenue

 

 

—

 

 

 

3

 

Total Revenues

 

 

1,475,899

 

 

 

1,557,632

 

Expenses:

 

 

 

 

Cost of goods manufactured and sold

 

 

196,457

 

 

 

245,331

 

Research and development

 

 

323,964

 

 

 

245,326

 

Selling, general and administrative

 

 

701,522

 

 

 

645,238

 

Amortization of acquired intangible assets

 

 

—

 

 

 

1,101

 

Total Expenses

 

 

1,221,943

 

 

 

1,136,996

 

Operating Income

 

 

253,956

 

 

 

420,636

 

Other Income, net:

 

 

 

 

 

 

  Interest income

 

 

45,304

 

 

 

42,450

 

  Interest expense

 

 

(12,277

)

 

 

(22,578

)

  Other income, net

 

 

4,467

 

 

 

3,242

 

Total Other Income, net

 

 

37,494

 

 

 

23,114

 

Income Before Income Taxes

 

 

291,450

 

 

 

443,750

 

Income Tax Provision

 

 

49,786

 

 

 

71,612

 

Net Income From Continuing Operations

 

 

241,664

 

 

 

372,138

 

Loss From Discontinued Operations — Net of Tax

 

 

—

 

 

 

(5,068

)

Net Income — GAAP

 

$

241,664

 

 

$

367,070

 

 

 

 

 

 

 

GAAP Earnings (Loss) Per Ordinary Share - Basic:

 

 

 

 

 

 

From continuing operations

 

$

1.47

 

 

$

2.25

 

From discontinued operations

 

$

—

 

 

$

(0.03

)

From net income

 

$

1.47

 

 

$

2.22

 

 

 

 

 

 

 

GAAP Earnings (Loss) Per Ordinary Share - Diluted:

 

 

 

 

 

 

From continuing operations

 

$

1.43

 

 

$

2.20

 

From discontinued operations

 

$

—

 

 

$

(0.03

)

From net income

 

$

1.43

 

 

$

2.17

 

 

 

 

 

 

 

Weighted Average Number of Ordinary Shares Outstanding:

 

 

 

 

 

 

Basic — GAAP and Non-GAAP

 

 

164,703

 

 

 

165,392

 

Diluted — GAAP and Non-GAAP

 

 

168,743

 

 

 

169,198

 

 

 

 

 

 

 

An itemized reconciliation between net income from continuing operations on a GAAP basis and EBITDA is as follows:

 

Net Income from Continuing Operations

 

$

241,664

 

 

$

372,138

 

Adjustments:

 

 

 

 

 

 

Depreciation expense

 

 

27,090

 

 

 

27,432

 

Amortization expense

 

 

75

 

 

 

1,101

 

Interest income

 

 

(45,304

)

 

 

(42,450

)

Interest expense

 

 

12,277

 

 

 

22,578

 

Income tax provision

 

 

49,786

 

 

 

71,612

 

EBITDA from Continuing Operations

 

 

285,588

 

 

 

452,411

 

EBITDA from Discontinued Operations

 

 

—

 

 

 

(5,790

)

EBITDA

 

$

285,588

 

 

$

446,621

 

Share-based compensation

 

 

98,716

 

 

 

96,636

 

Costs related to the acquisition of Avadel

 

 

9,662

 

 

 

—

 

Adjusted EBITDA

 

$

393,966

 

 

$

543,257

 

 

7

 

Alkermes plc and Subsidiaries

 

Selected Financial Information (Unaudited)

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets

 

December 31,

 

 

December 31,

 

(In thousands)

 

2025

 

 

2024

 

Cash, cash equivalents and total investments

 

$

588,360

 

 

$

824,816

 

Restricted cash

 

 

731,206

 

 

 

—

 

Receivables

 

 

334,025

 

 

 

384,528

 

Inventory

 

 

196,625

 

 

 

182,887

 

Prepaid expenses and other current assets

 

 

79,090

 

 

 

96,272

 

Property, plant and equipment, net

 

 

221,722

 

 

 

227,564

 

Intangible assets, net and goodwill

 

 

83,842

 

 

 

83,917

 

Deferred tax assets

 

 

125,815

 

 

 

154,835

 

Other assets

 

 

126,308

 

 

 

100,748

 

Total Assets

 

$

2,486,993

 

 

$

2,055,567

 

Accrued sales discounts, allowances and reserves

 

$

247,126

 

 

$

272,452

 

Other current liabilities

 

 

296,311

 

 

 

192,747

 

Long-term liabilities

 

 

124,261

 

 

 

125,391

 

Total shareholders' equity

 

 

1,819,295

 

 

 

1,464,977

 

Total Liabilities and Shareholders' Equity

 

$

2,486,993

 

 

$

2,055,567

 

 

 

 

 

 

 

Ordinary shares outstanding (in thousands)

 

 

165,607

 

 

 

162,177

 

 

 

 

 

 

 

 

This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Annual Report on Form 10-K for the year ended December 31, 2025, which the company intends to file in February 2026.

 

 

 

 

8

 

Alkermes plc and Subsidiaries

 

2026 Guidance — GAAP to EBITDA and Adjusted EBITDA

 

 

 

 

 

An itemized reconciliation between projected net loss on a GAAP basis, EBITDA and Adjusted EBITDA is as follows:

 

 

 

 

 

(In millions)

 

Amount

 

Projected Net Loss — GAAP

 

$

(125.0

)

   Adjustments:

 

 

 

Net interest expense

 

 

80.0

 

Depreciation and amortization expense

 

 

140.0

 

Income tax benefit

 

 

(20.0

)

Projected EBITDA

 

$

75.0

 

Share-based compensation expense

 

 

115.0

 

Costs related to the acquisition of Avadel

 

 

200.0

 

Projected Adjusted EBITDA

 

$

390.0

 

 

 

 

Projected Net Loss on a GAAP basis and Projected EBITDA and Projected Adjusted EBITDA reflect mid-points within ranges of estimated guidance.

 

 

 

 

9

 

Alkermes plc and Subsidiaries

 

Revenues for Calendar Year 2025 and 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

Three Months
Ended
March 31,
2025

 

 

Three Months
Ended
June 30,
2025

 

 

Three Months
Ended
September 30,
2025

 

 

Three Months
Ended
December 31,
2025

 

 

Year
Ended
December 31,
2025

 

Revenues:

 

 

 

 

 

 

 

 

 

 

VIVITROL

 

$

100,996

 

 

$

121,660

 

 

$

121,125

 

 

$

124,131

 

 

$

467,912

 

ARISTADA

 

 

73,475

 

 

 

101,295

 

 

 

98,050

 

 

 

97,224

 

 

 

370,044

 

LYBALVI

 

 

70,022

 

 

 

84,280

 

 

 

98,248

 

 

 

94,137

 

 

 

346,687

 

Total Proprietary Sales

 

 

244,493

 

 

 

307,235

 

 

 

317,423

 

 

 

315,492

 

 

 

1,184,643

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PARTNERED LONG-ACTING ANTIPSYCHOTICS (1)

 

 

26,874

 

 

 

34,135

 

 

 

33,931

 

 

 

34,256

 

 

 

129,196

 

VUMERITY

 

 

27,833

 

 

 

39,399

 

 

 

35,616

 

 

 

27,620

 

 

 

130,468

 

Key Commercial Product Revenues

 

 

299,200

 

 

 

380,769

 

 

 

386,970

 

 

 

377,368

 

 

 

1,444,307

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Legacy Product Revenues

 

 

7,310

 

 

 

9,888

 

 

 

7,215

 

 

 

7,179

 

 

 

31,592

 

Total Revenues

 

$

306,510

 

 

$

390,657

 

 

$

394,185

 

 

$

384,547

 

 

$

1,475,899

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

Three Months
Ended
March 31,
2024

 

 

Three Months
Ended
June 30,
2024

 

 

Three Months
Ended
September 30,
2024

 

 

Three Months
Ended
December 31,
2024

 

 

Year
Ended
December 31,
2024

 

Revenues:

 

 

 

 

 

 

 

 

 

 

VIVITROL

 

$

97,659

 

 

$

111,873

 

 

$

113,650

 

 

$

134,133

 

 

$

457,315

 

ARISTADA

 

 

78,870

 

 

 

86,049

 

 

 

84,652

 

 

 

96,616

 

 

 

346,187

 

LYBALVI

 

 

57,007

 

 

 

71,351

 

 

 

74,697

 

 

 

76,977

 

 

 

280,032

 

Total Proprietary Sales

 

 

233,536

 

 

 

269,273

 

 

 

272,999

 

 

 

307,726

 

 

 

1,083,534

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PARTNERED LONG-ACTING ANTIPSYCHOTICS (1)

 

 

65,391

 

 

 

82,297

 

 

 

60,876

 

 

 

51,267

 

 

 

259,831

 

VUMERITY

 

 

31,254

 

 

 

35,234

 

 

 

32,574

 

 

 

34,985

 

 

 

134,047

 

Key Commercial Product Revenues

 

 

330,181

 

 

 

386,804

 

 

 

366,449

 

 

 

393,978

 

 

 

1,477,412

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Legacy Product Revenues

 

 

20,188

 

 

 

12,327

 

 

 

11,694

 

 

 

36,008

 

 

 

80,217

 

Research and Development Revenues

 

 

3

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3

 

Total Revenues

 

$

350,372

 

 

$

399,131

 

 

$

378,143

 

 

$

429,986

 

 

$

1,557,632

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) - Includes RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, INVEGA TRINZA/TREVICTA and INVEGA HAFYERA/BYANNLI.

 

 

10

 

Alkermes plc and Subsidiaries

 

Amounts Included in Discontinued Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

Three Months
Ended
March 31,
2024

 

 

Three Months
Ended
June 30,
2024

 

 

Three Months
Ended
September 30,
2024

 

 

Three Months
Ended
December 31,
2024

 

 

Year Ended
December 31,
2024

 

Cost of goods manufactured and sold

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Research and development

 

 

2,516

 

 

 

3,913

 

 

 

481

 

 

 

(1,120

)

 

 

5,790

 

Selling, general and administrative

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Income tax (benefit) provision

 

 

(396

)

 

 

(613

)

 

 

(67

)

 

 

354

 

 

 

(722

)

Loss (income) from discontinued operations, net of tax

 

$

2,120

 

 

$

3,300

 

 

$

414

 

 

$

(766

)

 

$

5,068

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11